LMF ACQUISITION OPPORTUNITIES INC

NASDAQ: ICU (SeaStar Medical Holding Corpora)

Last update: 2 days ago, 12:20PM

0.599

0.04 (7.38%)

Previous Close 0.558
Open 0.545
Volume 873,919
Avg. Volume (3M) 6,557,378
Market Cap 9,670,549
Price / Sales 8.73
Price / Book 20.43
52 Weeks Range
0.305 (-49%) — 9.56 (1495%)
Earnings Date 11 Aug 2025 - 15 Aug 2025
Operating Margin (TTM) -1,304.44%
Diluted EPS (TTM) -2.34
Total Debt/Equity (MRQ) 64.25%
Current Ratio (MRQ) 0.960
Operating Cash Flow (TTM) -15.17 M
Levered Free Cash Flow (TTM) -11.89 M
Return on Assets (TTM) -144.37%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Bearish
Biotechnology (Global) Mixed Bearish
Stock SeaStar Medical Holding Corpora Mixed Mixed

AIStockmoo Score

-0.5
Analyst Consensus NA
Insider Activity NA
Price Volatility 0.5
Technical Moving Averages 0.0
Technical Oscillators -2.0
Average -0.50

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
ICU 10 M - - 20.43
LEGN 7 B - - 7.75
IMCR 2 B - - 4.69
JBIO 309 M - - -
ADAG 90 M - - 1.81
QTTB 27 M - - 3.55

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.

Sector Healthcare
Industry Biotechnology
% Held by Insiders 1.06%
% Held by Institutions 5.59%

Ownership

Name Date Shares Held
Tyche Wealth Partners Llc 31 Mar 2025 37,700
Trinity Financial Advisors Llc 30 Jun 2025 15,000
Great Valley Advisor Group, Inc. 31 Mar 2025 10,000

No data within this time range.

No data within this time range.

Date Type Details
16 Jul 2025 Announcement SeaStar Medical Grows Customer Base and Expands QUELIMMUNE Surveillance Registry
10 Jul 2025 Announcement SeaStar Medical Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
08 Jul 2025 Announcement SeaStar Medical Expands QUELIMMUNE Adoption for Critically Ill Pediatric Patients with Acute Kidney Injury (AKI)
02 Jul 2025 Announcement SeaStar Medical Announces Positive Nasdaq Listing Determination
25 Jun 2025 Announcement SeaStar Medical Reports Update on Nasdaq Listing Status
24 Jun 2025 Announcement SeaStar Medical Announces Two Feature Stories on QUELIMMUNE Adoption and Patient Testimonial of Life-Saving Therapy
20 Jun 2025 Announcement SeaStar Medical Announces Pricing of Up to $8 Million Public Offering
11 Jun 2025 Announcement AREVA Institute and SeaStar Medical Announce DoD Award of Prestigious Military Grant to AREVA Institute to Evaluate SeaStar Medical’s SCD Therapy to Advance Breakthrough Burn and Sepsis Research
28 May 2025 Announcement SeaStar Medical Announces CMS Coverage for Medicare and Medicaid Eligible Patients with Cardiorenal Syndrome Awaiting LVAD in Investigational Trial of SCD Therapy
14 May 2025 Announcement SeaStar Medical Reports First Quarter 2025 Financial Results and Provides Business Updates
13 May 2025 Announcement SeaStar Medical Reaches Interim Enrollment Target for NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury
07 May 2025 Announcement SeaStar Medical to Report First Quarter Financial Results on May 14, 2025
30 Apr 2025 Announcement SeaStar Medical Announces CEO Interview on Benzinga All Access to Occur Today at Approximately 10:50 am Eastern Time
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria